secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0000875045-22-000013
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q1 revenue down 6%, EPS miss; CEO Michel Vounatsos to step down; ADUHELM infrastructure cut
--------------------------------------------------------------------------------

- Q1 revenue $2.532B (-6% YoY); GAAP EPS $2.06, Non-GAAP EPS $3.62, both impacted by $0.76 ADUHELM write-offs
- Company to eliminate most ADUHELM commercial infrastructure after negative Medicare coverage decision
- Completed sale of biosimilar JV stake for up to $2.3B in April; reaffirmed 2022 financial guidance
- CEO Michel Vounatsos to step down; search for successor underway; he remains CEO during interim period

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504522000013/0000875045-22-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504522000013/biib-20220503.htm
  HTML page:      https://secwatch.observer/filing/0000875045-22-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer